Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


CrowdStrike punches above its weight in $612m IPO
Alphabet, Telstra and RackSpace-backed endpoint cybersecurity technology producer CrowdStrike will float above a range it had already increased.
Sansan sets price for $360m IPO
CyberAgent, GMO, Japan Post, Nikkei, Nippon Life, Recruit and Salesforce-backed Sansan priced its shares at the top of its range today and will raise $360m including the over-allotment option.
Peloton Interactive enters IPO cycle
Peloton has confidentially filed for an initial public offering in the US that would follow $995m of equity funding and provide exits for Comcast and Grace Beauty.
Inhibrx looks to inhabit public markets spot
The WuXi Biologics, Eli Lilly and Alexandria Real Estate Equities-backed cancer therapy developer is targeting $74.7m in its IPO.
Karuna clears path to $75m IPO
Having confidentially filed in late April, Karuna Therapeutics has publicly applied for an initial public offering that would raise $75m and provide exits to Nan Fung and PureTech Health.
Global Fashion Group gets ready for $338m IPO
Rocket Internet, Access Industries and Tengelmann-backed fashion e-commerce marketplace GFG could float in Germany next month.
The RealReal sets up shop for IPO
The second-hand luxury goods marketplace has set down a $100m target for an initial public offering that would offer an exit for Novel TMT Ventures.
Adaptive Biotechnologies switches to IPO mode
The immunotherapy technology developer has set a $230m target for an initial public offering that would offer exits to LabCorp, Illumina, Celgene and BD Biosciences.

Other News

Morphic moves toward public markets
Novo, GlaxoSmithKline, Pfizer, AbbVie, ShangPharma and Schrödinger are all in line for exits following the small-molecule drug developer's decision to file for an $86.3m initial public offering.
Cibus finds IPO too hard to stomach
Alexandria Real Estate Equities-backed gene-edited seed developer Cibus has withdrawn its IPO application three months after setting a price range that would have raised $107m at the upper end.
Atreca takes on public markets with $100m IPO
Solid tumour treatment developer Atreca has set a $100m target for an initial public offering that will provide GlaxoSmithKline with an exit.
Whispir winds toward public listing
The Telstra and Telkom-backed enterprise messaging software provider priced its shares at the foot of the IPO's range but is in line to raise $32.5m when it floats next month.
BridgeBio breaks $225m IPO filing
AIG-backed cancer and genetic disease developer BridgeBio Pharma has filed for a $225m initial public offering on the Nasdaq Global Market.
Stoke Therapeutics stakes out IPO spot
The genetic drug developer is targeting up to $86m in an IPO that would enable Alexandria Venture Investments to score an exit.

Editor's Picks

Uber arrives on public markets with $8.1bn
SoftBank Vision Fund is selling $245m of shares while PayPal is investing $500m in the ride hailing service, in the world's largest IPO since 2014.
Vision Fund envisages possible IPO
SoftBank is mulling the possibility of taking its $98.6bn Vision Fund public and is in talks with Oman over a commitment to a second fund.
Slack puts forward direct listing details
SoftBank Vision Fund owns more than 7% of the enterprise messaging platform developer, which could list at a valuation near $17bn.
Uber sets IPO terms to target $9bn
Uber is set to raise $7.9bn to $9bn if it floats within its range, while PayPal has agreed to invest another $500m through a private placement.
test reg